Clinical trial / 2014
Saffron extract and memantine produced similar cognitive outcomes in moderate to severe Alzheimer's.
In a 12-month double-blind trial, 68 patients with moderate to severe Alzheimer's disease received either 30 mg daily of saffron extract or 20 mg daily of memantine. Changes on the Severe Cognitive Impairment Rating Scale (P = 0.38) and Functional Assessment Staging (P = 0.87) did not differ significantly between treatments. Adverse event rates were also comparable between the two interventions.
- Study type
- Randomized controlled trial
- Who was studied
- 68 patients with moderate to severe Alzheimer's disease
- What was measured
- Severe Cognitive Impairment Rating Scale and Functional Assessment Staging scores
THE PAPER
Comparing the efficacy and safety of Crocus sativus L. with memantine in patients with moderate to severe Alzheimer's disease: a double-blind randomized clinical trial.
Farokhnia M, Shafiee Sabet M, Iranpour N, Gougol A, Yekehtaz H, Alimardani R, Farsad F, Kamalipour M, Akhondzadeh S. Hum Psychopharmacol, 2014.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.